

# Zachary T Bloomgarden

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9030981/zachary-t-bloomgarden-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103  
papers

2,764  
citations

27  
h-index

46  
g-index

231  
ext. papers

3,393  
ext. citations

7.3  
avg, IF

6.27  
L-index

#	Paper	IF	Citations
103	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 36, 108101	3.2	2
102	Diabetes during the COVID-19 pandemic: A global call to reconnect with patients and emphasize lifestyle changes and optimize glycemic and blood pressure control. <i>Journal of Diabetes</i> , <b>2020</b> , 12, 556-557	3.8	10
101	Early Life Famine Exposure, Ideal Cardiovascular Health Metrics, and Risk of Incident Diabetes: Findings From the 4C Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 1902-1909	14.6	8
100	Diabetes and COVID-19. <i>Journal of Diabetes</i> , <b>2020</b> , 12, 347-348	3.8	79
99	The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 25	8.7	10
98	Prognostic Significance of Long-term HbA Variability for All-Cause Mortality in the ACCORD Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 1185-1190	14.6	35
97	Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication. <i>Journal of Diabetes</i> , <b>2020</b> , 12, 8-9	3.8	
96	The Jiangnan diet, a healthy diet pattern for Chinese. <i>Journal of Diabetes</i> , <b>2020</b> , 12, 365-371	3.8	19
95	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. <i>Endocrine Practice</i> , <b>2020</b> , 26, 1196-1224	3.2	27
94	New insights into the older hypoglycemic agents in type 2 diabetes therapy. <i>Journal of Diabetes</i> , <b>2020</b> , 12, 844-847	3.8	
93	Predictive Value of Fasting Glucose, Postload Glucose, and Hemoglobin A on Risk of Diabetes and Complications in Chinese Adults. <i>Diabetes Care</i> , <b>2019</b> , 42, 1539-1548	14.6	51
92	Ideal Cardiovascular Health Metrics and Major Cardiovascular Events in Patients With Prediabetes and Diabetes. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 874-883	16.2	28
91	Introduction to the 2nd Heart in Diabetes (HiD) Meeting. <i>Journal of Diabetes</i> , <b>2019</b> , 11, 599-600	3.8	1
90	Implications of the recent CVOTs in type 2 diabetes: The right place for DPP-IV inhibitors today. <i>Diabetes Research and Clinical Practice</i> , <b>2019</b> , 157, 107906	7.4	
89	Temporal trends in ischemic stroke and anticoagulation therapy for non-valvular atrial fibrillation: effect of diabetes. <i>Journal of Diabetes</i> , <b>2017</b> , 9, 115-122	3.8	5
88	What strategies are implied by STRATEGY?. <i>Science China Life Sciences</i> , <b>2017</b> , 60, 319-320	8.5	
87	Is HbA 65 Years Old?. <i>Diabetes Care</i> , <b>2017</b> , 40, 526-528	14.6	9

86	AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES. <i>Endocrine Practice</i> , <b>2017</b> , 23, 1345-1349	3.2	3
85	Response to Comment on Bloomgarden et al. Is HbA 65 Years Old? <i>Diabetes Care</i> 2017;40:526-528. <i>Diabetes Care</i> , <b>2017</b> , 40, e154	14.6	
84	American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action. <i>Obesity</i> , <b>2017</b> , 25 Suppl 2, S34-S39	8	6
83	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). <i>American Heart Journal</i> , <b>2015</b> , 170, 675-682.e8	4.9	90
82	The future of diabetes. <i>Canadian Journal of Diabetes</i> , <b>2015</b> , 39, 204-5	2.1	0
81	Determinants of adherence to diabetes treatment. <i>Journal of Diabetes</i> , <b>2015</b> , 7, 864-71	3.8	39
80	Diabetes: Metformin and renal insufficiency-is 45, or even 30, the new 60?. <i>Nature Reviews Endocrinology</i> , <b>2015</b> , 11, 693-4	15.2	1
79	Helping people with diabetes to exercise. <i>Journal of Diabetes</i> , <b>2015</b> , 7, 150-2	3.8	3
78	American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. <i>Endocrine Practice</i> , <b>2015</b> , 21 Suppl 1, 1-87	3.2	252
77	Metformin associated with better cardiovascular outcomes than other glycaemic therapies. <i>Evidence-Based Medicine</i> , <b>2014</b> , 19, 103		
76	Basal insulin or longacting GLP-1 receptor agonists-making the right choice. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 439-41	18.1	1
75	Cohort profile: risk evaluation of cancers in Chinese diabetic individuals: a longitudinal (REACTION) study. <i>Journal of Diabetes</i> , <b>2014</b> , 6, 147-57	3.8	112
74	Diabetes and cancer relationships. <i>Journal of Diabetes</i> , <b>2013</b> , 5, 378-90	3.8	15
73	Current issues in GLP-1 receptor agonist therapy for type 2 diabetes. <i>Endocrine Practice</i> , <b>2012</b> , 18 Suppl 3, 6-26; quiz 27-8	3.2	6
72	Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. <i>Journal of Diabetes</i> , <b>2011</b> , 3, 67-73	3.8	88
71	World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease: part 4. <i>Diabetes Care</i> , <b>2011</b> , 34, e152-7	14.6	3
70	World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease: part 3. <i>Diabetes Care</i> , <b>2011</b> , 34, e140-5	14.6	3
69	World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease: part 2. <i>Diabetes Care</i> , <b>2011</b> , 34, e126-31	14.6	4

68	Troubling ethical questions from gestational diabetes trial. <i>Journal of Diabetes</i> , <b>2010</b> , 2, 1-4	3.8	4
67	Liraglutide and calcitonin. <i>Journal of Diabetes</i> , <b>2010</b> , 2, 223-4	3.8	1
66	Blood pressure and diabetic nephropathy. <i>Diabetes Care</i> , <b>2010</b> , 33, e30-5	14.6	6
65	Cardiovascular disease in diabetes. <i>Diabetes Care</i> , <b>2010</b> , 33, e49-54	14.6	12
64	Incretin concepts. <i>Diabetes Care</i> , <b>2010</b> , 33, e20-5	14.6	8
63	Type 1 diabetes and hypoglycemia. <i>Diabetes Care</i> , <b>2009</b> , 32, e1-4	14.6	
62	Topics in type 2 diabetes and insulin resistance. <i>Diabetes Care</i> , <b>2009</b> , 32, e13-9	14.6	1
61	Diabetes treatment. <i>Diabetes Care</i> , <b>2009</b> , 32, e25-30	14.6	5
60	Cardiovascular disease, neuropathy, and retinopathy. <i>Diabetes Care</i> , <b>2009</b> , 32, e64-8	14.6	7
59	A1C: recommendations, debates, and questions. <i>Diabetes Care</i> , <b>2009</b> , 32, e141-7	14.6	43
58	Nephropathy and other topics. <i>Diabetes Care</i> , <b>2009</b> , 32, e94-8	14.6	
57	Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes. <i>Diabetes Care</i> , <b>2008</b> , 31, 1461-6	14.6	11
56	Diabetes and obesity: part 2. <i>Diabetes Care</i> , <b>2008</b> , 31, 176-82	14.6	2
55	Diabetic nephropathy. <i>Diabetes Care</i> , <b>2008</b> , 31, 823-7	14.6	19
54	What role will SGLT2 inhibitors play in glycemic control?. <i>Cleveland Clinic Journal of Medicine</i> , <b>2008</b> , 75, 305-10	2.8	10
53	Gut hormones, obesity, polycystic ovarian syndrome, malignancy, and lipodystrophy syndromes. <i>Diabetes Care</i> , <b>2007</b> , 30, 1934-9	14.6	4
52	Prevention of cardiovascular disease. <i>Diabetes Care</i> , <b>2007</b> , 30, 423-31	14.6	1
51	Screening for and managing diabetic retinopathy: current approaches. <i>American Journal of Health-System Pharmacy</i> , <b>2007</b> , 64, S8-14	2.2	42

50	Does a structured patient education program improve glycemic control in individuals with type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2007</b> , 3, 390-1		0
49	The Avandia debate. <i>Diabetes Care</i> , <b>2007</b> , 30, 2401-8	14.6	19
48	Diabetic neuropathy. <i>Diabetes Care</i> , <b>2007</b> , 30, 1027-32	14.6	15
47	Type 1 diabetes and glucose monitoring. <i>Diabetes Care</i> , <b>2007</b> , 30, 2965-71	14.6	5
46	Exploring treatment strategies for type 2 diabetes. <i>Diabetes Care</i> , <b>2007</b> , 30, 2737-45	14.6	17
45	Diabetes and obesity: part 1. <i>Diabetes Care</i> , <b>2007</b> , 30, 3145-51	14.6	7
44	Diabetic retinopathy and diabetic neuropathy. <i>Diabetes Care</i> , <b>2007</b> , 30, 760-5	14.6	14
43	Achieving glycemic goals in type 2 diabetes. <i>Diabetes Care</i> , <b>2007</b> , 30, 174-80	14.6	10
42	Insulin resistance, dyslipidemia, and cardiovascular disease. <i>Diabetes Care</i> , <b>2007</b> , 30, 2164-70	14.6	35
41	Insulin resistance concepts. <i>Diabetes Care</i> , <b>2007</b> , 30, 1320-6	14.6	31
40	Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. <i>Diabetes Care</i> , <b>2006</b> , 29, 2137-9	14.6	180
39	Glycemic treatment in type 1 and type 2 diabetes. <i>Diabetes Care</i> , <b>2006</b> , 29, 2549-55	14.6	3
38	Weight control in individuals with diabetes. <i>Diabetes Care</i> , <b>2006</b> , 29, 2749-54	14.6	4
37	Measures of insulin sensitivity. <i>Clinics in Laboratory Medicine</i> , <b>2006</b> , 26, 611-33, vi	2.1	34
36	Developments in diabetes and insulin resistance. <i>Diabetes Care</i> , <b>2006</b> , 29, 161-7	14.6	3
35	Cardiovascular disease. <i>Diabetes Care</i> , <b>2006</b> , 29, 1160-6	14.6	
34	Cardiovascular complications of insulin resistance. <i>Metabolic Syndrome and Related Disorders</i> , <b>2005</b> , 3, 305-15	2.6	1
33	Non-alcoholic Fatty liver disease and malignancy as complications of insulin resistance. <i>Metabolic Syndrome and Related Disorders</i> , <b>2005</b> , 3, 316-27	2.6	2

32	Diabetic nephropathy. <i>Diabetes Care</i> , <b>2005</b> , 28, 745-51	14.6	26
31	2nd International Symposium on triglycerides and HDL: metabolic syndrome. <i>Diabetes Care</i> , <b>2005</b> , 28, 2577-84	14.6	8
30	Inflammation, atherosclerosis, and aspects of insulin action. <i>Diabetes Care</i> , <b>2005</b> , 28, 2312-9	14.6	43
29	Insulin resistance: causes and consequences. <i>International Review of Neurobiology</i> , <b>2005</b> , 65, 1-24	4.4	9
28	Approaching treatment of the insulin resistance syndrome. <i>Metabolic Syndrome and Related Disorders</i> , <b>2005</b> , 3, 328-31	2.6	1
27	Concepts of insulin resistance. <i>Metabolic Syndrome and Related Disorders</i> , <b>2005</b> , 3, 284-93	2.6	8
26	Diabetic retinopathy and neuropathy. <i>Diabetes Care</i> , <b>2005</b> , 28, 963-70	14.6	14
25	Thiazolidinediones. <i>Diabetes Care</i> , <b>2005</b> , 28, 488-93	14.6	29
24	Insulin resistance in children and in the polycystic ovarian syndrome. <i>Metabolic Syndrome and Related Disorders</i> , <b>2005</b> , 3, 294-304	2.6	1
23	Transplantation and islet topics. <i>Diabetes Care</i> , <b>2005</b> , 28, 213-9	14.6	1
22	Clinical diabetic neuropathy. <i>Diabetes Care</i> , <b>2005</b> , 28, 2968-74	14.6	11
21	Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. <i>Diabetes Care</i> , <b>2005</b> , 28, 1518-23	14.6	35
20	Aspects of blood pressure, lipid, and glycemic treatment. <i>Diabetes Care</i> , <b>2004</b> , 27, 264-9	14.6	3
19	Inpatient diabetes control: rationale. <i>Diabetes Care</i> , <b>2004</b> , 27, 2074-80	14.6	7
18	Dyslipidemia and the metabolic syndrome. <i>Diabetes Care</i> , <b>2004</b> , 27, 3009-16	14.6	16
17	Type 2 diabetes in the young: the evolving epidemic. <i>Diabetes Care</i> , <b>2004</b> , 27, 998-1010	14.6	148
16	Diabetes complications. <i>Diabetes Care</i> , <b>2004</b> , 27, 1506-14	14.6	52
15	Glycemic treatment: Control of glycemia. <i>Diabetes Care</i> , <b>2004</b> , 27, 1227-34	14.6	7

14	Inpatient diabetes control: approaches to treatment. <i>Diabetes Care</i> , <b>2004</b> , 27, 2272-7	14.6	9
13	Consequences of diabetes: cardiovascular disease. <i>Diabetes Care</i> , <b>2004</b> , 27, 1825-31	14.6	18
12	Prevention of obesity and diabetes. <i>Diabetes Care</i> , <b>2003</b> , 26, 3172-8	14.6	23
11	Approaches to cardiovascular disease and its treatment. <i>Diabetes Care</i> , <b>2003</b> , 26, 3342-8	14.6	6
10	Inflammation and insulin resistance. <i>Diabetes Care</i> , <b>2003</b> , 26, 1922-6	14.6	45
9	Inflammation and insulin resistance. <i>Diabetes Care</i> , <b>2003</b> , 26, 1619-23	14.6	30
8	Fat metabolism and diabetes: 2003 American Diabetes Association postgraduate course. <i>Diabetes Care</i> , <b>2003</b> , 26, 2198-203	14.6	4
7	Diabetes issues in women and children: polycystic ovary syndrome. <i>Diabetes Care</i> , <b>2003</b> , 26, 2457-63	14.6	3
6	American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. <i>Diabetes Care</i> , <b>2003</b> , 26, 1297-303	14.6	48
5	Adiposity and diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 2342-9	14.6	24
4	Treatment issues in type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 614-9	14.6	4
3	Treatment issues in type 1 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 230-6	14.6	11
2	Neuropathy, womensHealth, and socioeconomic aspects of diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 1085-94	14.6	4
1	Obesity, hypertension, and insulin resistance. <i>Diabetes Care</i> , <b>2002</b> , 25, 2088-97	14.6	46